PolyPid Ltd. Ordinary Shares
PYPDPolyPid Ltd. is a biotechnology company focused on developing and commercializing novel drug delivery and infection prevention solutions. The company utilizes its proprietary P-EDES™ (Polymer-based Endoscopic Delivery System) platform to enhance the efficacy of antimicrobial and anti-inflammatory treatments, primarily targeting surgical site infections and other serious medical conditions. Based in Israel, PolyPid aims to improve patient outcomes through innovative, locally applied therapies with a focus on safety and effectiveness.
Company News
PolyPid Ltd., a late-stage biopharma company, announced it will report Q4 2025 financial results on February 11, 2026. The company expects to submit its New Drug Application (NDA) for D-PLEX100, its lead product candidate for preventing abdominal colorectal surgical site infections, in early 2026 following positive phase 3 results. A conference c...
PolyPid, a late-stage biopharma company, announced successful results from its Phase 3 SHIELD II trial for its lead product candidate D-PLEX100, which demonstrated a statistically significant reduction in surgical site infections. The company has secured additional funding of $26.7 million through the exercise of warrants, which is expected to ex...
PolyPid, a late-stage biopharma company, announced that it will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11-12, 2025. The company's lead product candidate, D-PLEX100, is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections.
PolyPid, a late-stage biopharma company, will report its Q4 and full-year 2024 financial results and operational highlights on February 12, 2025. The company will host a conference call to discuss the results and provide an update on business operations.
PolyPid announced a positive recommendation from the DSMB to continue enrollment of its Phase 3 SHIELD II trial for D-PLEX100, a drug candidate for preventing surgical site infections. The company also announced a $41 million private placement financing to support the trial and potential future regulatory submissions.
